| Code | CSB-RA013481MB10HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is a research-grade biosimilar of VY7523 (also referred to as VY-TAU01 in Voyager disclosures), targeting MAPT (tau)—a microtubule-associated protein that helps regulate neuronal microtubule dynamics. In Alzheimer’s disease and other tauopathies, tau becomes abnormally modified (e.g., hyperphosphorylated), misfolds, and aggregates into paired helical filaments and neurofibrillary tangles, and accumulating evidence supports pathological tau “spread” through neural circuits, tracking with disease progression.
VY7523 is an intravenously administered, recombinant humanized IgG4 anti-tau antibody developed to inhibit the spread of pathological tau, and Voyager reports it targets a distinct C-terminal epitope with pathology-selective binding characteristics (in contrast to several earlier N-terminal anti-tau approaches). This biosimilar enables researchers to investigate tau biology and tauopathy mechanisms—including pathological tau recognition, aggregate seeding/spread models, and tau-targeting assay development/benchmarking—using a consistent antibody reagent independent of clinical formulation variables. It is also aligned with ongoing clinical-stage evaluation of VY7523 in early Alzheimer’s disease, making it useful as a translationally relevant comparator in tau-focused research workflows.
There are currently no reviews for this product.